“We knew for a long time that a diet rich in cholesterol impairs the liver’s ability to remove cholesterol from the blood, but we didn’t fully understand why,” explained Alan Saltiel, lead author of the study and professor of medicine at UC San Diego.
Cardiovascular diseases linked to high cholesterol remain a leading global health issue. While existing drugs like statins and PCSK9 inhibitors are effective, many patients fail to reach recommended cholesterol levels, while others struggle with side effects, leaving a significant unmet clinical need for new therapeutic options.
How Cholesterol-Rich Foods Sabotage the Body’s Natural Cleanup System
The liver plays an essential role in regulating blood cholesterol, acting as the body’s primary filtration system. It removes LDL cholesterol from circulation using structures on its cell surfaces called LDL receptors. The more of these receptors available, the efficiently the liver can clear excess cholesterol from the blood—a mechanism central to how current treatments work.
Through experiments in mice and human cells, the UC San Diego research team discovered a dietary trigger for this process. Consuming high levels of dietary cholesterol activates a protein called Ral, which initiates a cascade of reactions that leads to the loss of LDL receptors from the surface of liver cells. The researchers then pinpointed the role of an enzyme, cathepsin A (CTSA), in this mechanism. CTSA participates in the degradation of these receptors, further crippling the liver’s ability to manage cholesterol.
Understanding this mechanism of action—the specific biological process by which a substance produces an effect—is crucial. In this case, the mechanism involves a diet-induced protein activating an enzyme that destroys the very receptors responsible for cholesterol clearance, effectively sabotaging the body’s natural defense against high cholesterol.
Dietary Cholesterol Disables Liver LDL Removal via Specific Pathways
- A diet high in cholesterol doesn’t just add more LDL to your blood; it actively disables the liver’s ability to remove it.
- Researchers have found a specific biological pathway (involving the protein Ral and the enzyme CTSA) responsible for this disabling effect.
- An existing experimental drug, designed to block this pathway, has passed initial safety tests in humans and is now poised for efficacy trials.
A Promising Candidate: An Experimental Drug with a Head Start
The most promising aspect of this research is that scientists may not need to start from scratch in developing a new therapy. A CTSA inhibitor had previously been developed as a potential treatment for heart failure. Although that program was discontinued for strategic reasons, the experimental drug had already progressed to Phase 1 clinical trials, where its safety in humans was evaluated.
This prior experience could significantly shorten the development timeline for a new cholesterol-lowering application. The researchers hope to advance the drug into a Phase 2 clinical trial to specifically assess its efficacy in lowering LDL cholesterol in patients.
However, a critical distinction must be made: safety demonstrated in an initial phase is not the same as therapeutic efficacy. To date, the drug has not shown that it can lower cholesterol in people, and the results seen in animals must be confirmed through further clinical studies.
“Fortunately, there is an experimental drug that has already been tested and proven safe for humans. We hope to verify if it can be effective through a clinical trial,” stated Alan Saltiel.
The fact that this CTSA inhibitor is already a known, well-tolerated agent provides a substantial advantage.
If the CTSA inhibitor proves effective in subsequent trials, it would represent a new class of lipid-lowering therapy, distinct from the statins and PCSK9 inhibitors that dominate the current market. This is significant because it offers a potential solution for patients who are statin-intolerant or who have not achieved their target LDL levels with existing treatments.
| Therapeutic Target | Current Standard Therapies | Promising New Target (CTSA) |
|---|---|---|
| Mechanism of Action | ↑ LDL receptor expression (Statins), ↓ PCSK9-mediated receptor degradation | Inhibits CTSA-mediated degradation of LDL receptors |
| Stage of Development | Widely available, generic options exist | Phase 1 (Safety) complete in humans; Phase 2 (Efficacy) planned |
| Potential Patient Population | Broad, but some patients experience side effects or are non-responders | Statin-intolerant patients, non-responders to current therapies |
Consult a Doctor Before Changing Medication or Diet
The experimental CTSA inhibitor has not yet been approved for treating high cholesterol, and its efficacy and safety profile for this specific use are not yet established. Until a treatment is validated and approved, standard medical advice remains the cornerstone of care.
Individuals with high cholesterol should continue to monitor their levels as recommended by their healthcare provider and adhere to prescribed treatment plans. You should always consult a doctor or a qualified healthcare professional before making any changes to your medication or diet. Seek medical attention if you experience symptoms of cardiovascular distress, such as chest pain, shortness of breath, or sudden weakness, as these could be signs of a serious condition requiring immediate intervention.
The Path Forward: A New Hope for Patients with Refractory Hypercholesterolemia
The discovery of this metabolic pathway and the existence of a pre-tested drug offer a tangible, promising path forward.
For now, the focus remains on rigorous clinical validation. The journey from a promising laboratory finding to a standard treatment is long, but the findings from UC San Diego provide a clear and hopeful direction for future research and, ultimately, for the health of millions worldwide.
References
- Nature Publishing Group. “A novel metabolic pathway for dietary cholesterol-induced impairment of LDL clearance.” Nature.
- ScienceDaily. “Researchers identify a hidden factor that promotes bad cholesterol growth.” sciencedaily.com.
- Antena3.ro. “A man digging for 12 years in ‘Diamond Park’ finally found a yellow one, extremely valuable.” (Contextual source).
